Clotrimazole (Canesten®) 100 mg Vaginal Tablet 6-day Treatment

Clotrimazole Canesten 6 Vaginal Tablets 100mg
Clotrimazole Canesten 6 Vaginal Tablets 100mg Pack & Foil
Clotrimazole Canesten 6 Vaginal Tablets 100mg Foil
6 vaginal tablets 100mg

Clotrimazole (Canesten®) 100 mg Vaginal Tablet 6-day Treatment

Clotrimazole (Canesten®) 100 mg Vaginal Tablets 6-day treatment is clinically proven to provide targeted relief against the 6 main symptoms of Vaginal Yeast Infection by eliminating the fungi.

How do I know it’s Vaginal Yeast Infection?

6 main symptoms: 

  • Itching 
  • Swelling
  • Redness
  • Unusual discharge 
  • Burning 
  • Soreness 

 

Trust Canesten

Complete

Complete

Works to kill the root of the infection and relieve symptoms

Reliable

Reliable

Effectiveness based on decades of science and innovation

Convenient

Convenient

Clotrimazole (Canesten®) 100 mg Vaginal Tablet 6-day Treatment

Image

How to use?

Wash your hands thoroughly before and after using Clotrimazole (Canesten®)

Unless otherwise prescribed by the doctor, the vaginal tablet should be inserted as deeply as possible into the vagina in the evening before going to bed. Insertion is best achieved when lying back with the legs slightly drawn up.

Clotrimazole vaginal tablets need moisture in the vagina to dissolve completely, otherwise undissolved pieces of the vaginal tablet might crumble out of the vagina. To prevent this, it is important to insert the medication as deeply as possible into the vagina at bedtime. Should the vaginal tablet not dissolve completely within one night, the use of vaginal cream should be considered.

For treatment of vaginal infections use Clotrimazole (Canesten®) 100 mg Vaginal Tablet 6-day Treatment: 1 vaginal tablet to be introduced each evening on 6 successive days. Intended for use by adults and children 12 years of age and older.

Note: Pregnant women should strictly follow the instruction of their doctor.

Frequently asked questions about Vaginal Yeast Infection

    What is vaginal yeast infection?

    Vaginal yeast infection is a disease characterized by signs, symptoms of vaginitis, vaginitis and presence of fungi (mainly Candida). This is the second most common cause of vaginitis, and up to 75% of women of reproductive age have at least one vaginal yeast infection, [1,2] about 40-45% of patients will have the recurrent condition several times and 5-8% will develop recurrent vulvovaginal candidiasis (up to 10%) - defined as inflammation at least four times a year. [3,4]

    Symptoms of vaginal yeast infection include itching, burning, discharge, soreness, reddening, swelling.

    References:

    1. Mashburn J. Vaginal infections update. J Midwifery Womens Health 2012;57(6):629-34
    2. das Neves J, Pinto E, Teixeira B, Dias G, Rocha P, Cunha T, et al. Local treatment of vulvovaginal candidosis: general and practical considerations. Drugs. 2008;68(13):1787-802
    3. Sobel JD. Vulvovaginal candidosis. Lancet 2007;369:1961-71
    4. David W Denning, Matthew Kneale, Jack D Sobel, Riina Rautemaa-Richardson. Global burden of recurrent vulvovaginal candidiasis:a systematic review. Lancet Infect Dis 2018. Published Online August 2, 2018 http://dx.doi.org/10.1016/s1473-3099(18)30103-8
    What causes vaginal yeast infection?

    Candida albicans is the main causative agent of vaginal yeast infection, accounting for 80-92% of cases. The rest are other yeasts, mostly C. glabrata. These fungi are part of the vaginal microenvironment without causing symptoms in about 20% of healthy women. [1]

    Classification of vaginal yeast infection: uncomplicated and complicated. Uncomplicated VYI occurs at a low frequency (<4 times per year), with mild to moderate symptoms, most likely caused by Candida albicans, and the infected women have a normal immune system. Complicated VYI is characterizd by one of the following: persistent inflammation (4 or more times per year), severe vaginitis, non-Candida albicans or co-morbidities such as diabetes mellitus, immunosupression, use of immunosuppressive drugs. [2]

    References:

    1. Sobel JD. Gentital candidiasis. Medicine 2010;38(6):286-90
    2. Center for Disease Control and Prevention. Vaginal Discharge-STD Treatment Guidelines. 2015, 2021
    At what age are women most susceptible to vaginal yeast infection?

    Vaginal yeast infections occur mainly in women of reproductive age, with epidemiological data showing that at age 25, about 50% of women had at least one vaginal yeast infection. [1] Vaginal yeast infections are very rare in preteen girls, with rates beginning to increase at age 20 and reach the peak in the 30 to 40 age group. The rate of vaginal yeast infections is linked to the amount of estrogen in the body, as increased estrogen levels increase glycogen levels in vaginal tissues, creating a carbon source for Candida. This explains why vaginal yeast infections mainly occur at reproductive age. [2-4]

    References:

    1. Sobel JD, Faro S, Force R, et al. Vulvovaginal candidiasis: Epidemiologic, diagnostic and therapeutic considerations. Am J Obstet Gynecol 1998;178:203–211
    2. Cotch MF, Hillier SL, Gibbs RS, Eschenbach DA. Epidemiology and outcomes associated with moderate to heavy candida colonization during pregnancy. Vaginal Infections and Prematurity Study Group. Am J Obstet Gynecol 1998; 178: 374–80.
    3. Dennerstein GJ, Ellis DH. Oestrogen, glycogen and vaginal candidiasis. Aust N Z J Obstet Gynaecol 2001; 41: 326–28.
    4. Tarry W, Fisher M, Shen S, Mawhinney M. Candida albicans: the estrogen target for vaginal colonization. J Surg Res 2005; 129: 278–82.
    Why do vaginal yeast infections occur near the menstrual period?

    Vaginitis caused by Candidasis usually develops at the end of the ovulation cycle (within about a week before the start of the new menstrual cycle).[1,2] Vaginal yeast infections occur at this stage possibly due to the hormonal imbalance leading to reduced cell-mediated immune response.[1,2,3] 

    References:

    1. Corrigan EM, Clancy RL, Dunkley ML, Eyers FM, Beagley KW (1998). Cellular immunity in recurrent vulvovaginal candidiasis. Clinical and Experimental Immunology 111 (3): 574-578
    2. Kalo-Klein A, Witkin SS (1989). Candida albicans: cellular immune system interactions during different stages of the menstrual cycle. Journal of Obstetrics and Gynaecology 161 (5): 1132-1136
    3. Salinas-Muñoz L, Campos-Fernández R, Mercader E, Olivera-Valle I, Fernández-Pacheco C, Matilla L, García-Bordas J, Brazil JC, Parkos CA, Asensio F, Muñoz-Fernández MA, Hidalgo A, Sánchez-Mateos P, Samaniego R and Relloso M (2018) Estrogen Receptor-Alpha (ESR1) Governs the Lower Female Reproductive Tract Vulnerability to Candida albicans. Front. Immunol. 9:1033. doi: 10.3389/fimmu.2018.01033

    Read the full product information leaflet prior to use.           
    If symptoms, persist consult your doctor.

     

    ASC Reference No.:  
    B0011P011124C, B0058P011524C, B0060P011524C, B0061P011524C, B0062P011524C, B0063P011624C, B0048P012324C, B0053P012324C, B0054P012324C, B0179P012324C